At Onegene, we aim to tackle the toughest challenges of curing complex diseases. With an understanding of the desperation of patients, we focus our efforts on the most pressing needs. We believe that the next big step in treating complex, untreatable diseases will come from multi-modality drugs. These drugs are designed to modulate multiple signals in the disease micro-environment, providing a more comprehensive and surgical approach to treatment.
Enzyme-mediated protein-protein conjugation technology.
No need to optimize heterodimerization.
No limitation of choosing modalities.
High production yield for multispecifics.
Tetra-specific treatment for non-alcoholic steatohepatitis (NASH) by simultaneously addressing metabolic syndrome and inhibiting NLRP3 inflammasome activation.
Tri-specific approach for promoting T-cell based immune activation to efficiently regulate the tumor microenvironment (TME).